JOIN US FOR
2025 PEDS
A VIRTUAL CONFERENCE | OCT. 8-9, 2025
Implications of Change: Bridging Innovation and Investment to Advance Pediatric Cancer Therapies in a New Era
Implications of Change: Bridging Innovation and Investment to Advance Pediatric Cancer Therapies in a New Era
- Adapting to evolving regulatory priorities and policies to support new drug development.
- Leveraging patient and caregiver insights to enhance market positioning.
- Aligning scientific innovation with investment strategies to advance new therapies.
- Learning from biotech pioneers working to scale pediatric oncology breakthroughs.
Can't tune in live? All registered attendees will have access to recordings of the livestream.
PEDS Co-Chairs
Brenda Weigel, MD
Vice President of Clinical Research Industry Engagement St. Jude Children's Research Hospital
CureSearch Scientific Advisory Council Chair
Jeffrey Skolnik, MD
Vice President, Clinical Development
Inovio Pharmaceuticals Inc.
CureSearch Industry Advisory Council Chair
FEATURED SPEAKERS:
Preliminary program – full agenda coming soon
SESSION 1: Strategic Insights: Navigating Regulatory Frameworks to Accelerate Pediatric Oncology Innovation
Focuses on understanding evolving regulatory landscapes and how to align drug development strategies with policy changes for successful commercialization.
SESSION 2: Patient-Centered Value: Leveraging Insights to Drive Better Market Positioning in Pediatric Oncology
Explores the role of patient and caregiver perspectives in shaping research priorities, improving outcomes, and creating a compelling case for stakeholders and investors.
SESSION 3: From Research to ROI: Making the Case for Investing in Pediatric Cancer Therapies
Discusses strategies for aligning innovation with profitability, overcoming market challenges, and attracting investment to advance pediatric oncology ventures.
SESSION 4: Biotech Stories: Key Lessons in Scaling Pediatric Oncology Breakthroughs
Features case studies and best practices from biotech leaders who have navigated the pediatric oncology space, sharing lessons learned from both successes and setbacks in scaling breakthroughs from R&D to market.
